Clinical Trial

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019A in patients with relapsed/refractory multiple myeloma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-23
Trial Details
NCT Number NCT07429721
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Multiple Myeloma (MM)
Enrollment 24 participants
Start Date 2026-03-03
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-22